21 min listen
What a Decade of Investment Tells Us about the Health of Biotech
FromThe Bio Report
ratings:
Length:
14 minutes
Released:
Jun 25, 2015
Format:
Podcast episode
Description
A detailed view of funding of emerging therapeutic companies over the past ten years shows despite a rebound in venture financing, companies continue to struggle to find early-stage money. Nevertheless, the report shows the overall health of investment in the sector is thriving. We spoke to Dave Thomas, senior director of industry research and analysis for the Biotechnology Industry Organization and co-author of the report, about BIO’s findings, what therapeutic areas attracted the most financing, and what impact the capital markets have had on partnering and licensing activity.
Released:
Jun 25, 2015
Format:
Podcast episode
Titles in the series (100)
The Forces Bringing Disruptive Change to Healthcare: Scientific breakthroughs, innovations in technology, and the changing use of data are among the forces that are driving disruptive changes to healthcare. A new report from the IMS Institute for Healthcare Informatics highlights a number of these deve... by The Bio Report